Menu Search
Equities

Carmat SA

CXT:MUN

Carmat SA

Actions
  • Price (EUR)1.40
  • Today's Change-0.04 / -2.78%
  • Shares traded150.00
  • 1 Year change-71.46%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

  • Revenue in EUR (TTM)5.53m
  • Net income in EUR-53.35m
  • Incorporated2008
  • Employees162.00
  • Location
    Carmat SA36avenue de l'Europe, Immeuble l'EtendardVELIZY VILLACOUBLAY 78140FranceFRA
  • Phone+33 139456450
  • Fax+33 139456451
  • Websitehttps://www.carmatsa.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.